These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

577 related items for PubMed ID: 27701120

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Proarrhythmia Risk Assessment in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes Using the Maestro MEA Platform.
    Qu Y, Vargas HM.
    Toxicol Sci; 2015 Sep; 147(1):286-95. PubMed ID: 26117837
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Effects of Serum and Compound Preparation Methods on Delayed Repolarization Evaluation With Human iPSC-CMs.
    Wei F, Pence L, Woodling K, Bagam P, Beger R, Gamboa da Costa G, Pang L.
    Toxicol Sci; 2022 Jun 28; 188(1):48-61. PubMed ID: 35478258
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Sex-Related Differences in Drug-Induced QT Prolongation and Torsades de Pointes: A New Model System with Human iPSC-CMs.
    Huo J, Wei F, Cai C, Lyn-Cook B, Pang L.
    Toxicol Sci; 2019 Feb 01; 167(2):360-374. PubMed ID: 30247688
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Mechanisms of QT prolongation by buprenorphine cannot be explained by direct hERG channel block.
    Tran PN, Sheng J, Randolph AL, Baron CA, Thiebaud N, Ren M, Wu M, Johannesen L, Volpe DA, Patel D, Blinova K, Strauss DG, Wu WW.
    PLoS One; 2020 Feb 01; 15(11):e0241362. PubMed ID: 33157550
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Development of torsadogenic risk assessment using human induced pluripotent stem cell-derived cardiomyocytes: Japan iPS Cardiac Safety Assessment (JiCSA) update.
    Kanda Y, Yamazaki D, Osada T, Yoshinaga T, Sawada K.
    J Pharmacol Sci; 2018 Dec 01; 138(4):233-239. PubMed ID: 30415824
    [Abstract] [Full Text] [Related]

  • 32. Proarrhythmia Risk Assessment Using Electro-Mechanical Window in Human iPS Cell-Derived Cardiomyocytes.
    Yanagida S, Satsuka A, Hayashi S, Ono A, Kanda Y.
    Biol Pharm Bull; 2022 Dec 01; 45(7):940-947. PubMed ID: 35786601
    [Abstract] [Full Text] [Related]

  • 33. Cardiotoxicity Assessment of Drugs Using Human iPS Cell-Derived Cardiomyocytes: Toward Proarrhythmic Risk and Cardio-Oncology.
    Satsuka A, Kanda Y.
    Curr Pharm Biotechnol; 2020 Dec 01; 21(9):765-772. PubMed ID: 31264543
    [Abstract] [Full Text] [Related]

  • 34. International Multisite Study of Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Drug Proarrhythmic Potential Assessment.
    Blinova K, Dang Q, Millard D, Smith G, Pierson J, Guo L, Brock M, Lu HR, Kraushaar U, Zeng H, Shi H, Zhang X, Sawada K, Osada T, Kanda Y, Sekino Y, Pang L, Feaster TK, Kettenhofen R, Stockbridge N, Strauss DG, Gintant G.
    Cell Rep; 2018 Sep 25; 24(13):3582-3592. PubMed ID: 30257217
    [Abstract] [Full Text] [Related]

  • 35. Drug-induced functional cardiotoxicity screening in stem cell-derived human and mouse cardiomyocytes: effects of reference compounds.
    Himmel HM.
    J Pharmacol Toxicol Methods; 2013 Sep 25; 68(1):97-111. PubMed ID: 23702537
    [Abstract] [Full Text] [Related]

  • 36. Specific prediction of clinical QT prolongation by kinetic image cytometry in human stem cell derived cardiomyocytes.
    Pfeiffer ER, Vega R, McDonough PM, Price JH, Whittaker R.
    J Pharmacol Toxicol Methods; 2016 Sep 25; 81():263-73. PubMed ID: 27095424
    [Abstract] [Full Text] [Related]

  • 37. Application of optical action potentials in human induced pluripotent stem cells-derived cardiomyocytes to predict drug-induced cardiac arrhythmias.
    Lu HR, Hortigon-Vinagre MP, Zamora V, Kopljar I, De Bondt A, Gallacher DJ, Smith G.
    J Pharmacol Toxicol Methods; 2017 Sep 25; 87():53-67. PubMed ID: 28501647
    [Abstract] [Full Text] [Related]

  • 38. Patient-Specific and Gene-Corrected Induced Pluripotent Stem Cell-Derived Cardiomyocytes Elucidate Single-Cell Phenotype of Short QT Syndrome.
    Guo F, Sun Y, Wang X, Wang H, Wang J, Gong T, Chen X, Zhang P, Su L, Fu G, Su J, Yang S, Lai R, Jiang C, Liang P.
    Circ Res; 2019 Jan 04; 124(1):66-78. PubMed ID: 30582453
    [Abstract] [Full Text] [Related]

  • 39. Comprehensive In Vitro Proarrhythmia Assay (CiPA) Update from a Cardiac Safety Research Consortium / Health and Environmental Sciences Institute / FDA Meeting.
    Strauss DG, Gintant G, Li Z, Wu W, Blinova K, Vicente J, Turner JR, Sager PT.
    Ther Innov Regul Sci; 2019 Jul 04; 53(4):519-525. PubMed ID: 30157676
    [Abstract] [Full Text] [Related]

  • 40. Safety pharmacology studies using EFP and impedance.
    Obergrussberger A, Juhasz K, Thomas U, Stölzle-Feix S, Becker N, Dörr L, Beckler M, Bot C, George M, Fertig N.
    J Pharmacol Toxicol Methods; 2016 Jul 04; 81():223-32. PubMed ID: 27084108
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 29.